Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials-Reference-Cited by-同舟云学术

Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials

Published:2021-12 Issue: Volume:168 Page:103530
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Huo Xingfa,Shen Guoshuang,Liu Zhen,Liang Yuhua^ORCID,Li Jinming,Zhao Fuxing,Ren Dengfeng,Zhao Jiuda^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference44 articles.

1. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study;Adams;Annals of Oncology,2019

2. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study;Adams;Annals of Oncology,2019

3. Control of NK cell activation by immune checkpoint molecules;Beldi-Ferchiou;International journal of molecular sciences,2017

4. Treatment after progression in the era of immunotherapy;Billan;Lancet Oncol,2020

5. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination;Boutros;Nat Rev Clin Oncol,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET;mAbs;2024-01-12

2. Nanomedicine-mediated regulated cell death in cancer immunotherapy;Journal of Controlled Release;2023-12

3. Advancement of anti‐LAG‐3 in cancer therapy;The FASEB Journal;2023-10-17

4. Risk of interstitial lung disease with the use of programmed cell death 1(PD-1) inhibitor compared with programmed cell death ligand 1 (PD-L1) inhibitor in patients with breast cancer: A systematic review and meta-analysis;Cancer Pathogenesis and Therapy;2023-08

5. Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy;Cancers;2022-09-30